PatentApr 27, 2026, 08:02 AM
ALLR Stenoparib DRP Test Patent Allowance; Exclusivity into 2039
AI Summary
Allarity Therapeutics announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company's DRP companion diagnostic specific to stenoparib. This patent is expected to be formally granted within three months and would provide exclusivity at least into 2039 for stenoparib when used with the DRP companion diagnostic. This represents a significant step in Allarity's global strategy to expand and protect the commercial potential of stenoparib, particularly in the crucial U.S. market, as the company accelerates its development for Ovarian and other cancers.
Key Highlights
- USPTO issued Notice of Allowance for Allarity's stenoparib DRP companion diagnostic patent application.
- Patent expected to be formally granted within three months, subject to administrative procedures.
- Provides exclusivity for stenoparib when used with DRP companion diagnostic at least into 2039.
- Covers methods for predicting clinical benefit based on gene expression profiles and patient selection.
- Secures intellectual property protection for DRP technology in the US pharmaceutical market.
- Allarity previously secured European and Australian patents for Stenoparib DRP and holds 18 other DRP patents.
- Stenoparib is currently in two ongoing Phase 2 trials for Ovarian Cancer and one for SCLC.
Price Impact
More from ALLR